Phio Pharmaceuticals remains a clinical-stage biotech focused on developing PH-762 for skin cancer, recently reporting encouraging safety data and progression into toxicology studies. Despite these clinical advancements, the company’s financials highlight ongoing losses, steady cash burn, and reliance on equity offerings to fund operations. Meanwhile, Phio faces risk from Nasdaq minimum bid price compliance and supply chain uncertainties tied to trade policy shifts. Monitoring clinical milestones alongside capital adequacy and regulatory compliance will be crucial as the company seeks to build value in a competitive oncology space.